Merus (NASDAQ:MRUS) Earns "Outperform" Rating from William Blair

Merus (NASDAQ:MRUS - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at William Blair in a research report issued on Friday,RTT News reports. William Blair also issued estimates for Merus' FY2028 earnings at ($3.58) EPS.

Other analysts have also issued research reports about the stock. Piper Sandler assumed coverage on shares of Merus in a research note on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They set a "buy" rating and a $73.00 price objective on the stock. Citigroup lifted their price objective on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a report on Monday, December 9th. Wells Fargo & Company started coverage on Merus in a research note on Friday, February 7th. They set an "overweight" rating and a $91.00 price target for the company. Finally, Needham & Company LLC lowered their price objective on Merus from $85.00 to $83.00 and set a "buy" rating for the company in a research note on Friday. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $85.77.

Remove Ads

Merus Trading Down 1.8 %

NASDAQ MRUS traded down $0.83 on Friday, hitting $44.64. 1,056,444 shares of the company's stock were exchanged, compared to its average volume of 642,697. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The stock has a 50-day moving average of $42.10 and a 200-day moving average of $46.70. The stock has a market cap of $3.06 billion, a price-to-earnings ratio of -11.30 and a beta of 1.11.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million for the quarter, compared to analysts' expectations of $10.57 million. As a group, analysts predict that Merus will post -3.85 earnings per share for the current year.

Institutional Trading of Merus

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Merus during the fourth quarter valued at about $48,000. Wells Fargo & Company MN boosted its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Merus during the fourth quarter valued at approximately $60,000. Avior Wealth Management LLC bought a new position in shares of Merus during the 4th quarter valued at $76,000. Finally, Lazard Asset Management LLC bought a new position in shares of Merus during the fourth quarter valued at about $84,000. 96.14% of the stock is currently owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.